Fig. 2
Identification of erlotinib with higher drug sensitivity in PC patients with high-GRS. A Venn diagram for summarizing included candidate agents from CTD2, GDSC, and PRISM datasets; B Volcano plot of differential candidate agents between low-GRS and high-GRS groups. (Wilcoxon rank-sum test: adjust p < 0.05, and log2FC > 1); C The differential drug response analysis of current treatment for advanced pancreatic cancer; D The results of Spearman’s correlation analysis and differential drug response analysis of seven candidate agents; E Comparison of estimated erlotinib’s sensitivity (logAUC) between low-GRS and high-GRS groups; F Relationship between erlotinib’s sensitivity and the expression of ARNTL2 in PC; G Expression level of ARNTL2 between low-GRS and high-GRS groups